On the public citation graph

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

0 signed · 459 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/anie.201307906openalex-snapshot
Programmed Death‐1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
inferredcites →https://doi.org/10.1007/s13238-010-0022-1openalex-snapshot
A dimeric structure of PD-L1: functional units or evolutionary relics?
inferredcites →https://doi.org/10.1016/j.ccell.2015.03.001openalex-snapshot
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
inferredcites →https://doi.org/10.1016/j.chembiol.2014.09.001openalex-snapshot
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
inferredcites →https://doi.org/10.1016/j.coi.2015.01.006openalex-snapshot
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
inferredcites →https://doi.org/10.1016/j.coph.2015.05.011openalex-snapshot
PD-1/PD-L1 inhibitors
inferredcites →https://doi.org/10.1016/j.molmed.2014.10.009openalex-snapshot
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
inferredcites →https://doi.org/10.1016/j.str.2015.09.010openalex-snapshot
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
inferredcites →https://doi.org/10.1021/bi000930vopenalex-snapshot
Chalcone Derivatives Antagonize Interactions between the Human Oncoprotein MDM2 and p53
inferredcites →https://doi.org/10.1021/bi048135vopenalex-snapshot
Thermodynamic Stability of Carbonic Anhydrase: Measurements of Binding Affinity and Stoichiometry Using ThermoFluor
inferredcites →https://doi.org/10.1021/ja052143xopenalex-snapshot
Monitoring the Effects of Antagonists on Protein−Protein Interactions with NMR Spectroscopy
inferredcites →https://doi.org/10.1021/ja901863hopenalex-snapshot
Robust NMR Screening for Lead Compounds Using Tryptophan-Containing Proteins
inferredcites →https://doi.org/10.1021/jm070365vopenalex-snapshot
An NMR-Based Antagonist Induced Dissociation Assay for Targeting the Ligand−Protein and Protein−Protein Interactions in Competition Binding Experiments
inferredcites →https://doi.org/10.1038/nature13904openalex-snapshot
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
inferredcites →https://doi.org/10.1038/nature14011openalex-snapshot
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
inferredcites →https://doi.org/10.1038/nprot.2007.321openalex-snapshot
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
inferredcites →https://doi.org/10.1038/nrd1343openalex-snapshot
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
inferredcites →https://doi.org/10.1038/nrd4591openalex-snapshot
Combination cancer immunotherapy and new immunomodulatory targets
inferredcites →https://doi.org/10.1038/nrd4779openalex-snapshot
FDA approves first immunotherapy combo
inferredcites →https://doi.org/10.1056/nejmoa1200694openalex-snapshot
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
inferredcites →https://doi.org/10.1073/pnas.0712278105openalex-snapshot
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
inferredcites →https://doi.org/10.1074/jbc.m112.448126openalex-snapshot
Structure and Interactions of the Human Programmed Cell Death 1 Receptor
inferredcites →https://doi.org/10.1093/nar/gkt940openalex-snapshot
PDBsum additions
inferredcites →https://doi.org/10.1107/97809553602060000865openalex-snapshot
PHENIX: a comprehensive Python-based system for macromolecular structure solution
inferredcites →https://doi.org/10.1107/s0021889807021206openalex-snapshot
Phaser crystallographic software
inferredcites →https://doi.org/10.1107/s0021889812011715openalex-snapshot
XDSAPP : a graphical user interface for the convenient processing of diffraction data using XDS
inferredcites →https://doi.org/10.1107/s0907444905036693openalex-snapshot
Scaling and assessment of data quality
inferredcites →https://doi.org/10.1107/s0907444909029436openalex-snapshot
electronic Ligand Builder and Optimisation Workbench (eLBOW): A tool for ligand coordinate and restraint generation
inferredcites →https://doi.org/10.1107/s0907444909047337openalex-snapshot
XDS
inferredcites →https://doi.org/10.1107/s0907444909052925openalex-snapshot
PHENIX : a comprehensive Python-based system for macromolecular structure solution
inferredcites →https://doi.org/10.1107/s0907444910007493openalex-snapshot
Features and development of Coot
inferredcites →https://doi.org/10.1107/s0907444911001314openalex-snapshot
REFMAC 5 for the refinement of macromolecular crystal structures
inferredcites →https://doi.org/10.1126/science.274.5292.1531openalex-snapshot
Discovering High-Affinity Ligands for Proteins: SAR by NMR
inferredcites →https://doi.org/10.1126/science.7529940openalex-snapshot
A Hot Spot of Binding Energy in a Hormone-Receptor Interface
inferredcites →https://doi.org/10.1126/science.aaa8172openalex-snapshot
The future of immune checkpoint therapy
inferredcites →https://doi.org/10.1140/epjp/i2015-15141-2openalex-snapshot
The macromolecular crystallography beamlines at BESSY II of the Helmholtz-Zentrum Berlin: Current status and perspectives
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-3271openalex-snapshot
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1200/jco.2014.32.15_suppl.8021openalex-snapshot
Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4679402openalex-extracted
Styryl Carbamates Backbones for the Discovery of TME-Disruptors Agents
inferred← citeshttps://doi.org/10.1002/1873-3468.15034openalex-snapshot
Platycodin D reduces PD ‐ L1 levels by inhibiting LXR ‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cells
inferred← citeshttps://doi.org/10.1002/adma.202517019openalex-snapshot
Emerging Biomaterials Blocking PD‐1/PD‐L1 Pathway for Cancer Therapy
inferred← citeshttps://doi.org/10.1002/ange.201707707openalex-snapshot
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
inferred← citeshttps://doi.org/10.1002/ange.201707816openalex-snapshot
Kleine Moleküle, ganz groß: niedermolekulare immunonkologische Kombinationstherapien
inferred← citeshttps://doi.org/10.1002/ange.201710407openalex-snapshot
Der Immuncheckpoint PD‐1/PD‐L1: Gibt es Therapieoptionen jenseits der Antikörper?
inferred← citeshttps://doi.org/10.1002/ange.202504233openalex-snapshot
De Novo Design of Structure‐Tunable Multivalent Targeting Chimeras for Tumor‐Targeted PD‐L1 Degradation and Potentiated Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/anie.201707707openalex-snapshot
Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint
inferred← citeshttps://doi.org/10.1002/anie.201707816openalex-snapshot
Small Molecules Drive Big Improvements in Immuno‐Oncology Therapies
inferred← citeshttps://doi.org/10.1002/anie.201710407openalex-snapshot
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
inferred← citeshttps://doi.org/10.1002/anie.202504233openalex-snapshot
De Novo Design of Structure‐Tunable Multivalent Targeting Chimeras for Tumor‐Targeted PD‐L1 Degradation and Potentiated Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/ardp.202300583openalex-snapshot
A combined approach of structure‐based virtual screening and NMR to interrupt the PD‐1/PD‐L1 axis: Biphenyl‐benzimidazole containing compounds as novel PD‐L1 inhibitors
inferred← citeshttps://doi.org/10.1002/ardp.70292openalex-snapshot
Small Molecules, Big Impact: Structural Innovations Driving PD‐L1 Checkpoint Modulation
inferred← citeshttps://doi.org/10.1002/cmdc.202000760openalex-snapshot
The Stone Guest: How Does pH Affect Binding Properties of PD‐1/PD‐L1 Inhibitors?
inferred← citeshttps://doi.org/10.1002/cmdc.202100264openalex-snapshot
Identification of the FDA‐Approved Drug Pyrvinium as a Small‐Molecule Inhibitor of the PD‐1/PD‐L1 Interaction
inferred← citeshttps://doi.org/10.1002/cmdc.202500179openalex-snapshot
Progress in the Research and Development of Biphenyl Small Molecules Targeting PD‐1/PD‐L1 as Potential Antitumor Drug Candidates
inferred← citeshttps://doi.org/10.1002/cmdc.202500972openalex-snapshot
Research Progress and Clinical Translation Challenges of Small‐Molecule Inhibitors Targeting PD‐L1
inferred← citeshttps://doi.org/10.1002/cmdc.70287openalex-snapshot
Design, Synthesis, and Biological Evaluation of Small‐Molecule PD‐1/PD‐L1 Inhibitors Bearing a Rigid Benz[d]oxazole Skeleton
inferred← citeshttps://doi.org/10.1002/ctd2.139openalex-snapshot
Gut microbiome and neurosurgery: Implications for treatment
inferred← citeshttps://doi.org/10.1002/iid3.693openalex-snapshot
BMS‐202, a PD‐1/PD‐L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways
inferred← citeshttps://doi.org/10.1002/med.21530openalex-snapshot
Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
inferred← citeshttps://doi.org/10.1002/med.70001openalex-snapshot
The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins
inferred← citeshttps://doi.org/10.1002/minf.202200254openalex-snapshot
Identification of a PD1/PD‐L1 inhibitor by structure‐based pharmacophore modelling, virtual screening, molecular docking and biological evaluation**
inferred← citeshttps://doi.org/10.1002/slct.201800095openalex-snapshot
Identification of Small‐Molecule Inhibitors of PD‐1/PD‐L1 Protein‐Protein Interaction
inferred← citeshttps://doi.org/10.1002/slct.202302813openalex-snapshot
Molecular modeling studies of Indoline Scaffold derivatives as PD‐1/PD‐L1 pathway inhibitors by QSAR, molecular docking and molecular dynamics simulation techniques
inferred← citeshttps://doi.org/10.1002/slct.202401008openalex-snapshot
Design of Biphenyl‐Type Programmed Cell Death‐Ligand 1 Inhibitors Using 3D‐QSAR, Molecular Docking, and Molecular Dynamics Simulation
inferred← citeshttps://doi.org/10.1002/slct.202503129openalex-snapshot
Discovery of Novel PD‐L1 Inhibitors Using Machine Learning and Molecular Simulations
inferred← citeshttps://doi.org/10.1002/smll.201903881openalex-snapshot
Immune Checkpoint Blockade Mediated by a Small‐Molecule Nanoinhibitor Targeting the PD‐1/PD‐L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-981-13-0773-7_7openalex-snapshot
Small Molecule Inhibitors Targeting New Targets of Protein-Protein Interactions
inferred← citeshttps://doi.org/10.1007/978-981-13-1639-5_5openalex-snapshot
Cellular Automata (CA) Model for Protein
inferred← citeshttps://doi.org/10.1007/978-981-15-3266-5_22openalex-snapshot
Small Molecular Immune Modulators as Anticancer Agents
inferred← citeshttps://doi.org/10.1007/s00044-021-02728-3openalex-snapshot
A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?
inferred← citeshttps://doi.org/10.1007/s00044-022-02926-7openalex-snapshot
Design, synthesis, and structure–activity relationships of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as inhibitors of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immune checkpoint pathway
inferred← citeshttps://doi.org/10.1007/s00044-023-03127-6openalex-snapshot
Progress on biphenyl derivatives as PD-1/PD-L1 inhibitors
inferred← citeshttps://doi.org/10.1007/s00280-019-03995-zopenalex-snapshot
Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design
inferred← citeshttps://doi.org/10.1007/s00384-018-3202-8openalex-snapshot
Current status of immunotherapy in metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s10822-020-00306-0openalex-snapshot
Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach
inferred← citeshttps://doi.org/10.1007/s10989-025-10707-0openalex-snapshot
Development of Novel Short Peptide Inhibitor Targeted to Immune Checkpoint PD-1 LBD
inferred← citeshttps://doi.org/10.1007/s11030-021-10208-4openalex-snapshot
Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint
inferred← citeshttps://doi.org/10.1007/s11030-022-10509-2openalex-snapshot
Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis
inferred← citeshttps://doi.org/10.1007/s11030-023-10697-5openalex-snapshot
Probing the origins of programmed death ligand-1 inhibition by implementing machine learning-assisted sequential virtual screening techniques
inferred← citeshttps://doi.org/10.1007/s11684-021-0886-xopenalex-snapshot
Emerging immunological strategies: recent advances and future directions
inferred← citeshttps://doi.org/10.1007/s12032-023-02183-7openalex-snapshot
A multitier virtual screening of antagonists targeting PD-1/PD-L1 interface for the management of triple-negative breast cancer
inferred← citeshttps://doi.org/10.1007/s13238-016-0337-7openalex-snapshot
Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
inferred← citeshttps://doi.org/10.1007/s13238-017-0412-8openalex-snapshot
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
inferred← citeshttps://doi.org/10.1007/s40242-019-8310-7openalex-snapshot
Design, Synthesis, Biological Activity and Molecular Docking Study of Coumarin Derivatives Bearing 2-Methylbiphenyl Moiety
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.12400-xopenalex-snapshot
Cancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research
inferred← citeshttps://doi.org/10.1016/b978-0-443-15530-7.00009-9openalex-snapshot
Immune-oncological drug nivolumab
inferred← citeshttps://doi.org/10.1016/bs.mie.2019.05.053openalex-snapshot
Elucidating the role of an immunomodulatory protein in cancer: From protein expression to functional characterization
inferred← citeshttps://doi.org/10.1016/bs.pmch.2019.11.001openalex-snapshot
Small molecules—Giant leaps for immuno-oncology
inferred← citeshttps://doi.org/10.1016/j.ab.2018.02.003openalex-snapshot
PD-1/PD-L1 inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance spectroscopy
inferred← citeshttps://doi.org/10.1016/j.abb.2021.109059openalex-snapshot
Targeting cryptic-orthosteric site of PD-L1 for inhibitor identification using structure-guided approach
inferred← citeshttps://doi.org/10.1016/j.actbio.2021.08.013openalex-snapshot
Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.02.031openalex-snapshot
YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.03.019openalex-snapshot
Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment
inferred← citeshttps://doi.org/10.1016/j.apsb.2022.04.007openalex-snapshot
Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
inferred← citeshttps://doi.org/10.1016/j.bbagen.2017.11.022openalex-snapshot
Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective
inferred← citeshttps://doi.org/10.1016/j.bcp.2020.113821openalex-snapshot
Protein homodimer sequestration with small molecules: Focus on PD-L1
inferred← citeshttps://doi.org/10.1016/j.bcp.2020.114042openalex-snapshot
Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer
inferred← citeshttps://doi.org/10.1016/j.bcp.2021.114522openalex-snapshot
Synthesis and pharmacological evaluation of novel resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign toxicity profiles for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.bcp.2022.115113openalex-snapshot
Strategies for developing PD-1 inhibitors and future directions
inferred← citeshttps://doi.org/10.1016/j.bioelechem.2021.107742openalex-snapshot
Ultrasensitive electrochemical determination of the cancer biomarker protein sPD-L1 based on a BMS-8-modified gold electrode
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2025.123380openalex-snapshot
An artificial-enzyme-equipped immunoregulator blocks platelet-mediated breast cancer hematogenous metastasis
inferred← citeshttps://doi.org/10.1016/j.bioorg.2021.104833openalex-snapshot
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)
inferred← citeshttps://doi.org/10.1016/j.bioorg.2021.105432openalex-snapshot
Structure–activity relationship and biological evaluation of 12 N-substituted aloperine derivatives as PD-L1 down-regulatory agents through proteasome pathway
inferred← citeshttps://doi.org/10.1016/j.bioorg.2022.105769openalex-snapshot
Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through “ring fusion” strategy
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107376openalex-snapshot
Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107813openalex-snapshot
Design, synthesis, and antitumor activity evaluation of 1,2,3-triazole derivatives as potent PD-1/PD-L1 inhibitors
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107874openalex-snapshot
Discovery of Daclatasvir as a potential PD-L1 inhibitor from drug repurposing
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.107899openalex-snapshot
New benzophenone analogs from Nigrospora sphaerica and their inhibitory activity against PD-1/PD-L1 interactions
inferred← citeshttps://doi.org/10.1016/j.bioorg.2024.108036openalex-snapshot
Beyond peptides: Unveiling the design strategies, structure activity correlations and protein-ligand interactions of small molecule inhibitors against PD-1/PD-L1
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.109238openalex-snapshot
PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.116257openalex-snapshot
Small molecule and PROTAC molecule experiments in vitro and in vivo, focusing on mouse PD-L1 and human PD-L1 differences as targets
inferred← citeshttps://doi.org/10.1016/j.biopha.2025.118695openalex-snapshot
Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway
inferred← citeshttps://doi.org/10.1016/j.bmc.2021.116038openalex-snapshot
Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective
inferred← citeshttps://doi.org/10.1016/j.bmc.2021.116579openalex-snapshot
Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors
inferred← citeshttps://doi.org/10.1016/j.bmc.2022.117001openalex-snapshot
Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction
inferred← citeshttps://doi.org/10.1016/j.bmc.2023.117490openalex-snapshot
Aryl azoles based scaffolds for disrupting tumor microenvironment
inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118238openalex-snapshot
Advances in cancer immunotherapy using small-molecular inhibitors targeting the PD-1/PD-L1 interaction
inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118268openalex-snapshot
Comparative druggability of PD-1/PD-L1 inhibitors (A56, HD10): Cross-species differences in PD-L1 exposure and efficacy
inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118366openalex-snapshot
Discovery of bromobenzyl phenyl ether derivative YPD-29B: a novel pre-clinical compound targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction
inferred← citeshttps://doi.org/10.1016/j.bmcl.2019.01.028openalex-snapshot
Fragment-based screening of programmed death ligand 1 (PD-L1)
inferred← citeshttps://doi.org/10.1016/j.bmcl.2019.07.027openalex-snapshot
Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction
inferred← citeshttps://doi.org/10.1016/j.bmcl.2021.128403openalex-snapshot
Design, synthesis, and structure–activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128647openalex-snapshot
Discovery of 4-phenylindolines containing a (5-cyanopyridin-3-yl)methoxy moiety as potent inhibitors of the PD-1/PD-L1 interaction
inferred← citeshttps://doi.org/10.1016/j.bmcl.2025.130187openalex-snapshot
Development and evaluation of biphenyl-based small-molecule radiotracers for PET imaging of PD-L1 in tumor
inferred← citeshttps://doi.org/10.1016/j.bmcl.2025.130458openalex-snapshot
Discovery of novel indoline derivatives as potent small molecule PD-L1 inhibitors
inferred← citeshttps://doi.org/10.1016/j.canlet.2020.08.009openalex-snapshot
A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity
inferred← citeshttps://doi.org/10.1016/j.cbi.2025.111741openalex-snapshot
Investigating the interaction mechanism of five flavonoids and PD-L1 based on multi-spectroscopy and molecular dynamics
inferred← citeshttps://doi.org/10.1016/j.cclet.2022.107762openalex-snapshot
Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma
inferred← citeshttps://doi.org/10.1016/j.cclet.2025.112263openalex-snapshot
Hydrazide-based HDAC inhibitors and PROTAC degraders in drug discovery: Recent developments and therapeutic applications
inferred← citeshttps://doi.org/10.1016/j.chembiol.2024.04.002openalex-snapshot
Molecular glues for protein-protein interactions: Progressing toward a new dream
inferred← citeshttps://doi.org/10.1016/j.compbiolchem.2022.107804openalex-snapshot
Discovery of small-molecule PD-1/PD-L1 antagonists through combined virtual screening and experimental validation
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2025.110589openalex-snapshot
Integrated computational pipeline for advanced sampling-based investigation and alternative inhibition of the programmed cell death protein I pathway
inferred← citeshttps://doi.org/10.1016/j.csbj.2023.06.006openalex-snapshot
Theoretical and experimental studies on the interaction of biphenyl ligands with human and murine PD-L1: Up-to-date clues for drug design
inferred← citeshttps://doi.org/10.1016/j.drudis.2026.104814openalex-snapshot
Drug discovery strategies targeting B7-H3 (CD276) in lung and gastric cancers: From biological validation to next-generation small molecules, biologics and cell-based immunotherapies
inferred← citeshttps://doi.org/10.1016/j.ejmech.2018.08.028openalex-snapshot
Recent advances in small molecule based cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.ejmech.2018.10.044openalex-snapshot
Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?
inferred← citeshttps://doi.org/10.1016/j.ejmech.2019.03.012openalex-snapshot
Novel multitarget inhibitors with antiangiogenic and immunomodulator properties
inferred← citeshttps://doi.org/10.1016/j.ejmech.2019.111856openalex-snapshot
Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold
inferred← citeshttps://doi.org/10.1016/j.ejmech.2019.111876openalex-snapshot
Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
inferred← citeshttps://doi.org/10.1016/j.ejmech.2020.112377openalex-snapshot
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113170openalex-snapshot
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113356openalex-snapshot
If small molecules immunotherapy comes, can the prime be far behind?
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113377openalex-snapshot
Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113637openalex-snapshot
Discovery of phenyl-linked symmetric small molecules as inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction
inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113998openalex-snapshot
Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction
inferred← citeshttps://doi.org/10.1016/j.ejmech.2022.114343openalex-snapshot
Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115465openalex-snapshot
Inside PD-1/PD-L1,2 with their inhibitors
inferred← citeshttps://doi.org/10.1016/j.ejmech.2023.115468openalex-snapshot
Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116267openalex-snapshot
Recent advances and mechanisms of action of PD-L1 degraders as potential therapeutic agents
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116433openalex-snapshot
Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116622openalex-snapshot
Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116756openalex-snapshot
Inducing or enhancing protein-protein interaction to develop drugs: Molecular glues with various biological activity
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.118132openalex-snapshot
Drugging the undruggable: Chemical and biological insights into molecular glues in the pipeline
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.176144openalex-snapshot
Develop a PD-1-blockade peptide to reinvigorate T-cell activity and inhibit tumor progress
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2023.123266openalex-snapshot
Study on endogenous inhibitors against PD-L1: cAMP as a potential candidate
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2023.126811openalex-snapshot
Design and evaluation of α-helix-based peptide inhibitors for blocking PD-1/PD-L1 interaction
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2024.130921openalex-snapshot
Computational analysis of PD-L1 dimerization mechanism induced by small molecules and potential dynamical properties
inferred← citeshttps://doi.org/10.1016/j.ijpharm.2022.121466openalex-snapshot
Evaluation of immune-modulating drugs for use in drug-eluting microsphere transarterial embolization
inferred← citeshttps://doi.org/10.1016/j.intimp.2025.115271openalex-snapshot
In vivo modulation of the tumor microenvironment: anti-tumor effects of combination therapy of fucoidan and small molecule immune checkpoint inhibitor BMS-202
inferred← citeshttps://doi.org/10.1016/j.isci.2020.101960openalex-snapshot
Human and mouse PD-L1: similar molecular structure, but different druggability profiles
inferred← citeshttps://doi.org/10.1016/j.it.2020.04.004openalex-snapshot
Opportunities for Small Molecules in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.jare.2024.01.024openalex-snapshot
Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers
inferred← citeshttps://doi.org/10.1016/j.lfs.2021.119813openalex-snapshot
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway
inferred← citeshttps://doi.org/10.1016/j.matdes.2025.115185openalex-snapshot
Nano-enabled combinatorial immunotherapy of colorectal cancer via small molecular PD-L1 blockade and photodynamic therapy
inferred← citeshttps://doi.org/10.1016/j.molstruc.2023.135900openalex-snapshot
Synthesis and preliminary evaluation of aminophenol derivatives as molecular glues blocking PD-1/PD-L1 interaction
inferred← citeshttps://doi.org/10.1016/j.molstruc.2023.136487openalex-snapshot
Synthesis and evaluation of indole-containing derivatives as C-linked PD-L1 inhibitors for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.molstruc.2026.145825openalex-snapshot
Design, synthesis, characterization, and biological evaluation of novel iminocoumarin derivatives: In vitro anticancer activity against NSCLC and ex vivo NLRP3 inflammasome inhibition supported by docking and ADMET studies
inferred← citeshttps://doi.org/10.1016/j.neo.2021.01.001openalex-snapshot
Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.pep.2019.105520openalex-snapshot
Screening and production of an affibody inhibiting the interaction of the PD-1/PD-L1 immune checkpoint
inferred← citeshttps://doi.org/10.1016/j.pep.2020.105766openalex-snapshot
Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2021.107870openalex-snapshot
Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer
inferred← citeshttps://doi.org/10.1016/j.phymed.2024.155370openalex-snapshot
Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade
inferred← citeshttps://doi.org/10.1016/j.phymed.2026.158481openalex-snapshot
Silibinin is a natural molecular glue that inhibits PD-L1 glycomaturation
inferred← citeshttps://doi.org/10.1016/j.phymed.2026.158609openalex-snapshot
Discovery of natural product-derived rosavin as a programmed death-ligand 1 inhibitor for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.rechem.2024.101372openalex-snapshot
Styryl carbamate backbones for the discovery of TME-disrupting agents
inferred← citeshttps://doi.org/10.1016/j.rechem.2026.103877openalex-snapshot
Machine-learning-guided discovery and prioritization of PD-L1 inhibitors: An open-source KNIME workflow with curated bioactivity data, molecular fingerprints, and applicability-domain assessment
inferred← citeshttps://doi.org/10.1016/j.smim.2019.101295openalex-snapshot
Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications
inferred← citeshttps://doi.org/10.1016/j.str.2017.06.011openalex-snapshot
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2
inferred← citeshttps://doi.org/10.1016/s0145-2126(17)30210-2openalex-snapshot
Mutations in DNA Methylation Pathway and Number of Driver Mutations Predict Response to Azacitidine in Myelodysplastic Syndromes
inferred← citeshttps://doi.org/10.1017/9781108774956openalex-snapshot
Quantum Chemistry Simulation of Biological Molecules
inferred← citeshttps://doi.org/10.1021/acs.analchem.5c00486openalex-snapshot
Virtual Screening Combined with Phase Transition-FRET for Discovery of Small-Molecule FcRn Antagonists
inferred← citeshttps://doi.org/10.1021/acs.biochem.7b00655openalex-snapshot
The Too Many Faces of PD-L1: A Comprehensive Conformational Analysis Study
inferred← citeshttps://doi.org/10.1021/acs.biochem.9b00822openalex-snapshot
Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide
inferred← citeshttps://doi.org/10.1021/acs.jcim.4c00455openalex-snapshot
Design, Synthesis, and Biological Evaluation of Chroman Derivatives as PD-1/PD-L1 Antagonists
inferred← citeshttps://doi.org/10.1021/acs.jcim.5c01335openalex-snapshot
Novel GPU Engines for Virtual Screening of Giga-Sized Libraries Identify Inhibitors of Challenging Targets
inferred← citeshttps://doi.org/10.1021/acs.jcim.9b00337openalex-snapshot
Mapping the Binding Hot Spots on Human Programmed Cell Death 1 and Its Ligand with Free-Energy Simulations
inferred← citeshttps://doi.org/10.1021/acs.jctc.5c00736openalex-snapshot
Cooperative Free Energy: Induced Protein–Protein Interactions and Cooperative Solvation in Ternary Complexes
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c01260openalex-snapshot
Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c01262openalex-snapshot
Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c01329openalex-snapshot
Design, Synthesis, and Biological Evaluation of Linear Aliphatic Amine-Linked Triaryl Derivatives as Potent Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction with Promising Antitumor Effects In Vivo
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c01362openalex-snapshot
Recent Advances in the Development of PD-L1 Modulators: Degraders, Downregulators, and Covalent Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c00370openalex-snapshot
Design, Synthesis, and Evaluation of o -(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c00392openalex-snapshot
Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c00957openalex-snapshot
Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c01409openalex-snapshot
Interfering with the Tumor–Immune Interface: Making Way for Triazine-Based Small Molecules as Novel PD-L1 Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c01422openalex-snapshot
Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.1c01682openalex-snapshot
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c00539openalex-snapshot
Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.2c01801openalex-snapshot
Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00205openalex-snapshot
Discovery and Optimization of Novel Biphenyl Derivatives Bearing Cyclopropyl Linkage as Potent Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00254openalex-snapshot
Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00264openalex-snapshot
Novel 4-Arylindolines Containing a Pyrido[3,2- d ]pyrimidine Moiety as the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Inhibitors for Tumor Immunotherapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00449openalex-snapshot
Molecular Glue Discovery: Current and Future Approaches
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00731openalex-snapshot
Design, Synthesis, and Antitumor Activity Evaluation of 2-Arylmethoxy-4-(2,2′-dihalogen-substituted biphenyl-3-ylmethoxy) Benzylamine Derivatives as Potent PD-1/PD-L1 Inhibitors
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c00942openalex-snapshot
Design, Synthesis, and Activity Evaluation of Novel Dual-Target Inhibitors with Antifungal and Immunoregulatory Properties
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c01141openalex-snapshot
Discovery and Crystallography Study of Novel Biphenyl Ether and Oxadiazole Thioether (Non-Arylmethylamine)-Based Small-Molecule PD-1/PD-L1 Inhibitors as Immunotherapeutic Agents
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c02143openalex-snapshot
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c02259openalex-snapshot
Discovery of Novel Proteolysis-Targeting Chimera Molecules as Degraders of Programmed Cell Death-Ligand 1 for Breast Cancer Therapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c02342openalex-snapshot
Development and In Vivo Evaluation of Small-Molecule Ligands for Positron Emission Tomography of Immune Checkpoint Modulation Targeting Programmed Cell Death 1 Ligand 1
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.3c02362openalex-snapshot
Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00102openalex-snapshot
Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00128openalex-snapshot
Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c00296openalex-snapshot
Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c01449openalex-snapshot
Peptide-Mediated Small Molecule Lysosome-Targeting Chimeras for Targeted Degradation of Membrane and Intracellular Proteins
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c02206openalex-snapshot
Design, Synthesis, Evaluation, and SAR of 5-Phenylisoindoline Derivatives, a Potent Class of Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c02510openalex-snapshot
Discovery of Novel and Highly Potent Dual PD-L1/Histone Deacetylase 6 Inhibitors with Favorable Pharmacokinetics for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c00344openalex-snapshot
Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c00379openalex-snapshot
Extracellular HSP90-Facilitated Degradation of Extracellular and Membrane Proteins by Bifunctional Small Molecules
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c00979openalex-snapshot
Synthesis and Biological Evaluation of Novel 99mTc-Tricarbonyl-Labeled Small-Molecule SPECT Tracers for PD-L1 Imaging
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c02527openalex-snapshot
Novel Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors Modulate Lipid Metabolism for Enhanced Tumor Immunotherapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c03784openalex-snapshot
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6c00363openalex-snapshot
Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6c00674openalex-snapshot
One Face, Three Solutions: Structural Convergence in PD-L1 Inhibition across Antibodies, Macrocycles, and Small Molecules
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.6c01174openalex-snapshot
Discovery and Crystallographic Study of Water-Soluble Quaternary Ammonium-Based PD-1/PD-L1 Inhibitors with Anti-Angiogenic Activity
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.7b00293openalex-snapshot
Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.8b00541openalex-snapshot
Structure–Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.8b00990openalex-snapshot
Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.9b00312openalex-snapshot
Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.9b00795openalex-snapshot
Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction
inferred← citeshttps://doi.org/10.1021/acs.jpcb.3c00911openalex-snapshot
Predicting a Stable Dimeric Form of the PD1-PDL1 Complex: Implications for Understanding the PD1 Activation Mechanism
inferred← citeshttps://doi.org/10.1021/acs.orglett.2c01642openalex-snapshot
Synthesis of Tunable Fluorescent Imidazole-Fused Heterocycle Dimers
inferred← citeshttps://doi.org/10.1021/acsabm.6c01076openalex-snapshot
Peptide-Functionalized Gold Nanoparticles Targeting PD-L1: Design via a Molecular Dynamic Driven Approach and Further Experimental Validation
inferred← citeshttps://doi.org/10.1021/acsami.0c11156openalex-snapshot
Rational Design of a Robust Antibody-like Small-Molecule Inhibitor Nanoplatform for Enhanced Photoimmunotherapy
inferred← citeshttps://doi.org/10.1021/acsami.1c08290openalex-snapshot
Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade
inferred← citeshttps://doi.org/10.1021/acsami.4c06415openalex-snapshot
Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1021/acscentsci.3c00003openalex-snapshot
What Makes a Good Protein–Protein Interaction Stabilizer: Analysis and Application of the Dual-Binding Mechanism
inferred← citeshttps://doi.org/10.1021/acschembio.0c00264openalex-snapshot
mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1)
inferred← citeshttps://doi.org/10.1021/acschembio.7b00708openalex-snapshot
Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action
showing the first 200 of 420 · page through all 420
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.